Large, Blinded Prospective Study Demonstrates that GeneSight Improves Clinical Outcomes in Patients with Treatment Resistant Major Depressive Disorder SALT LAKE CITY, Utah, Jan. 4, 2019 –Myriad Genetics, Inc. (NASDAQ: MYGN),…
Data Presented at APA Show 50 Percent Improvement in Remission and 30 Percent Improvement in Response for GeneSight versus Treatment as Usual (TAU) SALT LAKE CITY, May 7, 2018 –…
2,000 Patient Study Will Leverage GeneSight Test to Guide Therapy Selection SALT LAKE CITY, Nov. 10, 2017 – Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today…
GeneSight Demonstrated Statistically Significant Improvement in the Gold Standard Clinical Outcomes of Remission and Response SALT LAKE CITY, Nov. 02, 2017 (GLOBE NEWSWIRE) — Assurex Health, a wholly-owned subsidiary of…
Positive Results Presented at the 25th World Congress of Psychiatric Genetics Salt Lake City, Oct. 19, 2017 – Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced…
